Summary

One of the current standards of care for the first-line therapy of metastatic colorectal cancer (mCRC) is combination chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus the angiogenesis inhibitor, bevacizumab (BEV). The Phase 3 AIO KRK 0207 study [NCT00973609] showed that active maintenance therapy with FP+BEV or BEV alone, compared with no treatment, prolonged the time-to-failure of strategy and progression-free survival in patients with mCRC after induction treatment [Arnold D et al. Ann Oncol. 2014 (abstr O-0027); J Clin Oncol. 2014 (abstr 3503)].